Clinical studies have shown that patients with acute myeloid leukemia (AML) with a higher percentage of cDC1 and higher expression of activation molecules such as CD86 and HLA-DR are more likely to respond to targeted immunotherapies, including PD-1 inhibitors and peptide vaccines, and achieve longer remissions [143,171]. This evidence concerns the gene CD86 and acute myeloid leukemia.